REDUCING THE IMPACT
ASADRP is focused on decreasing the clinical impact of alcohol and substance abuse for service members, veterans and the American public. (Photo by U.S. Army Acquisi- tion Support Center/KatarzynaBialasiewicz/Getty Images)
Te new drug application is the vehicle toward FDA approval and the final step before pharmaceutical sales. Te information gathered from these animal and human clinical trials become a part of the application.
To complement these industry collaborations, the Department of Veterans Affairs and the National Institutes of Health are help- ing to build a strong infrastructure, Williams said, allowing the discovery of new treatments and helping to bridge what is known in translational research as the “valley of death.” Tese collabora- tions provide the funding and support needed to cross this valley, allowing medical research to become a new therapy or treatment and ultimately help the patient who needs it.
A CONSORTIUM CASE IN POINT Another consortium partnership funded by ASADRP is the Insti- tute for Translational Neuroscience, which collaborates with 22 research institutions with expertise in alcohol and drug addic- tion, PTSD and veterans health.
Dr. Jennifer Mitchell, the consortium’s principal investigator and associate professor at the University of California, San Francisco, said it focuses on rapidly and inexpensively developing thera- peutics by identifying and testing compounds that are already approved by the FDA for other indications and could work for alcohol and substance abuse disorders.
“We are currently testing three promising compounds,” said Mitchell. “Te first is oxytocin, which is a neuropeptide that is naturally produced in the brain and important for social bond- ing. Oxytocin can be administered as a nasal spray and has been used to treat a number of indications [mostly related to child- birth] for many years.
“More recent findings suggest that oxytocin can also block some aspects of alcohol intoxication, can decrease alcohol craving and can decrease signs of PTSD,” she continued. “We are trying to gather funds to conduct a Phase III study of oxytocin in people with alcohol use disorder and PTSD, and we hope to someday see
HTTPS: / /
ASC.ARMY.MIL
57
SCIENCE & TECHNOLOGY
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132 |
Page 133 |
Page 134 |
Page 135 |
Page 136 |
Page 137 |
Page 138 |
Page 139 |
Page 140 |
Page 141 |
Page 142 |
Page 143 |
Page 144 |
Page 145 |
Page 146 |
Page 147 |
Page 148 |
Page 149 |
Page 150 |
Page 151 |
Page 152
